Meeting
2022 ASCO Gastrointestinal Cancers Symposium
Encorafenib, cetuximab, and cytotoxic chemotherapy combinations in BRAFV600E CRC murine models.
Authors
Melanie Nicole Woods
University of Texas MD Anderson Cancer Center, Houston, TX
Melanie Nicole Woods , Vincenzo De Falco , Claudia Prisco , Giulia Martini , Luigi Pio Guerrera , Valentina Belli , Teresa Troiani , Van K. Morris II, John Paul Y.C. Shen , Hey Min Lee , Oscar Villarreal , Alexey Sorokin , Preeti Kanikarla Marie , Fortunato Ciardiello , Scott Kopetz , Stefania Napolitano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Colorectal Cancer,Anal Cancer
Sub Track
Translational Research
DOI
10.1200/JCO.2022.40.4_suppl.145
Abstract #
145
Poster Bd #
K9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Real-world outcomes of patients with BRAF-mutated mCRC treated in the United States.
First Author: Matthew Braithwaite
Poster
2024 ASCO Annual Meeting
SWOG S2107: Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer.
First Author: Van K. Morris II
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Retrospective analysis of the real-world demographics, clinical characteristics, and treatment patterns in metastatic CRC among patients treated with encorafenib in combination with cetuximab in the United States.
First Author: Aparna Raj Parikh
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).
First Author: Zev A. Wainberg